

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : A61K 35/74, 31/715</p>		<p>A1</p>	<p>(11) International Publication Number: WO 98/32452 (43) International Publication Date: 30 July 1998 (30.07.98)</p>
<p>(21) International Application Number: PCT/US98/01852 (22) International Filing Date: 29 January 1998 (29.01.98)</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>	
<p>(30) Priority Data: 08/790,989 29 January 1997 (29.01.97) US</p>		<p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(71) Applicant: VANDERBILT UNIVERSITY [US/US]; 305 Kirkland Hall, Nashville, TN 37240 (US).</p>			
<p>(72) Inventors: HELLERQVIST, Carl, G.; 9014 Carondelet Place, Brentwood, TN 37027 (US). WAMIL, Barbara, D.; 7913 Amber Hills Lane, Nashville, TN 37221-3229 (US).</p>			
<p>(74) Agents: SACHDEVA, Gurjeev, K.; Cooley Godward LLP, 3000 El Camino Real, Five Palo Alto Square, Palo Alto, CA 94306-2155 (US) et al.</p>			
<p>(54) Title: TREATMENT OF CHRONIC INFLAMMATORY DISEASES WITH CM101/GBS TOXIN</p>			
<p>(57) Abstract</p> <p>A method of treating a chronic inflammatory disease such as rheumatoid arthritis or psoriasis includes treating a patient with a toxin derived from Group B β-hemolytic <i>Streptococcus</i> bacteria. The purified GBS toxin, or CM101, may be administered intravenously to the patient in repeated doses.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**TREATMENT OF CHRONIC INFLAMMATORY DISEASES
WITH CM101/GBS TOXIN**

5

INTRODUCTION

Field of the Invention

This invention relates to the treatment of chronic inflammatory diseases, including rheumatoid arthritis and psoriasis.

10 **Background**

Chronic inflammatory diseases such as rheumatoid arthritis (RA) and psoriasis are debilitating diseases affecting millions of people.

RA is a systemic, chronic, inflammatory disease affecting approximately 1-2% of the world's population. The manifestations of RA are usually most severe in the joints. The most frequently affected joints are the proximal interphalangeal and metacarpophalangeal joints in the hands and the metatarsophalangeal joints in the feet. The shoulders, elbows, knees, ankles, and wrists are also common targets of RA. Joints affected by RA ("active" joints) are characteristically tender. Accordingly, RA sufferers often experience pain and impaired mobility. While the severity and progression of RA vary considerably among affected individuals, RA patients as a group have twice the mortality rate of their unaffected counterparts. This decrease in life expectancy appears to be due in part to the side effects of current RA treatments.

In the initial stages of RA, the synovium of the affected joint becomes enlarged and inflamed. Expansion of the synovium is accompanied by angiogenesis and neovascularization. This, in turn, facilitates infiltration into the area by plasma cells, lymphocytes, and macrophages. As inflammatory cells accumulate within it, the synovium becomes edematous and hyperplastic. Neutrophils infiltrate the synovial fluid and cluster on the surface of the synovium. Fibrin deposition also occurs in the joint space. The synovial fluid increases in

volume and turbidity with the accumulation of neutrophils, mononuclear cells and occasional red blood cells.

Chronic inflammation causes the synovium to thicken and extend over the articular surface, forming villi which project into the joint space. This aberrant and highly vascularized structure is called a pannus. The pannus invades and erodes the underlying cartilage, with the most active cartilage destruction occurring at the interface between pannus and cartilage. Cartilage destruction is effectuated by collagenase and metallo-proteinases secreted by the inflammatory cells of the pannus. Erosion eventually extends to the subchondral bone, articular capsule and ligaments. Osteoclastic molecules released by the inflammatory cells and synoviocytes allow the synovium to penetrate into the bone and form juxto-articular erosions, subchondral cysts, and osteoporosis.

After the cartilage has been destroyed, the pannus fills the entire joint space, laying down fibrous bands which bridge the opposing bones. As this fibrous ankylosis becomes calcified, a resulting bony ankylosis forms which fuses the opposing bones and prevents the joint from functioning.

RA is an autoimmune disease wherein patients have antinuclear antibodies and antibodies directed at autologous proteins such as immunoglobulin G (IgG), collagen, and cytoskeletal filamentous proteins. Rheumatoid factors (RFs) are autoantibodies found in serum and synovial fluid which bind to the Fc portion of IgG. RFs have been implicated in the pathogenesis of RA. When RFs bind IgGs, complement-activating immune complexes are formed. Activated complement causes the release of vasoactive and chemotactic substances which attract neutrophils and macrophages to the immune complex. As these cells ingest and destroy the immune complexes, they release molecules which cause inflammation and protein degradation and which attract other cells that contribute to RA pathogenesis. Because RFs are synthesized in joints and RFs of the IgG class are self-associating, immune complexes are frequently localized to joints. Nevertheless, immune complexes do circulate in some patients and are thought to cause the extra-articular manifestations of RA such as rheumatoid nodules, reactive amyloidosis and acute vasculitis.

The evidence that RA has autoimmune origins is supported by the finding that injecting avian type II collagen into rats or mice causes them to develop antibodies that recognize the rodent's endogenous collagen. The resulting autoimmune response, which is known as "collagen arthritis," mimics the physiological symptoms of RA such as joint inflammation (Trentham et al., *Autoimmunity to type II collagen: an experimental model of arthritis*, J. of Experimental Medicine, 146: 857 (1977); Courtenay et al., Nature, 283: 666). Collagen arthritis is a well established model system for the study of RA (Staines & Wooley, *Collagen arthritis-what can it teach us?*, British Journal of Rheumatology, 1994, 33: 798 (1994)).

The primary method for treating RA is through the administration of drugs which suppress the immune system or reduce inflammation. The two main classes of inflammation inhibitors are corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs).

Corticosteroids are not favored RA medications because, although they can achieve dramatic short-term improvements in RA, long-term treatment is not advisable due to serious side effects and diminished effectiveness of the drug. Short-term corticosteroid treatment is also far from ideal because arthritis symptoms rapidly reappear, often with increased severity, after treatment has stopped. Although corticosteroids such as prednisone can suppress clinical symptoms of RA, the drugs do not prevent RA-mediated joint destruction. Furthermore, typical corticosteroid side effects include: peptic ulcer, hypertension, diabetes mellitus, and glaucoma.

NSAIDs such as aspirin, ibuprofen, and indomethacin are frequently prescribed for RA. Although these drugs can reduce swelling in active joints by inhibiting prostaglandin synthesis, their poor penetration of joint spaces necessitates administration of high doses, and such high doses tend to cause gastrointestinal irritation, ulceration, and bleeding. NSAIDs affect prostaglandin-regulate processes not associated with the inflammation process. NSAIDs are also potent renal toxins, and so are also inadequate for treatment of RA.

Patients with severe active RA may be treated with immunosuppressants such as cyclophosphamide, methotrexate, and azathioprine. While they can reduce

inflammation, these drugs affect the patient's entire immune system and have serious side effects including liver disease, bone marrow suppression, and increased risk of malignancy.

Other RA medications include penicillamine, chloroquine, 5 hydroxychloroquine, and gold salts. All have potentially serious side effects. D-penicillamine can cause bone marrow suppression, proteinuria, and nephrosis. Deaths resulting from penicillamine treatment have also been reported. Patients treated with hydroxychloroquine or chloroquine must be monitored for signs of irreversible retinal damage. Gold can induce toxic reactions in the form of 10 dermatitis, renal failure or hepatitis, and its efficacy at treating arthritis is questionable.

Psoriasis sufferers include approximately 1-3% of the population in the United States and an even higher percentage of Northern Europeans. Psoriasis is a chronic inflammatory skin disease in which the patient's skin exhibits recurrent 15 erythematous plaques. These appear as white or silvery, scaling lesions on the skin, especially in the area of the scalp, elbows, knees, back, and buttocks. The accompanying burning and itching may cause discomfort. In severe forms, severe arthritis or exfoliation develops, as well.

The psoriatic lesions exhibit epidermal hyperplasia, infiltration of 20 inflammatory cells, and abnormalities of dermal capillary networks. They are believed to result from epithelial cell hyperproliferation, neovascularization, and, of course, the infiltration of inflammatory cells into the area. Angiogenesis is believed to be necessary to maintain the inflammation and direct neutrophils and lymphocytes into the psoriatic lesion. Additionally, psoriasis patients have 25 autoantibodies directed at the stratum corneum. These autoantibodies are implicated in the pathogenesis of the disease.

Current treatment for psoriasis includes lubricating creams or oils, 30 keratolytics, and topical corticosteroids. For severe forms of the disease, methotrexate may be given, but its high potential for toxicity requires rigidly controlled treatment conditions, including careful monitoring of hematologic, renal, and hepatic function. Treatment for psoriatic arthritis is similar to that for

RA, with some exceptions. For example, antimalarials may aggravate the underlying psoriasis.

RA and psoriasis are diseases characterized by unregulated angiogenesis. Vascular endothelial growth factor (VEGF) has been implicated in driving such unregulated angiogenesis by stimulating endothelial cells lining nearby microvessels to proliferate and begin the process leading to new blood vessel formation. There is evidence that VEGF receptors are overexpressed by endothelial cells that line the blood vessels supplying the inflammatory reactions leading to these disorders. (Dvorak, *Int. Arch. Allergy. Immunol.*, May-June 1995).

What is needed is a treatment method for chronic inflammatory diseases such as RA and psoriasis. There is a need for a compound which inhibits the signs and symptoms of these diseases, and particularly reduces the pain, inflammation, joint swelling, and lesions associated with these diseases.

Furthermore, what is needed is a treatment method, and particularly a compound, which is easy to administer and which is nontoxic.

SUMMARY OF THE INVENTION

One aspect of the present invention is a method for treating patients with chronic inflammatory diseases, such as RA and psoriasis, by administering CM101, a bacterial polysaccharide that is generally nontoxic, to the patient in order to reduce the likelihood of formation of new blood vessels.

RA patients treated with CM101 experience reduction of pain, joint swelling, and acute inflammation, and also experience inhibition of pannus formation. CM101 may be administered before the onset of RA, when the first symptoms of RA are detected, and/or at later stages in RA progression.

Psoriasis patients treated with CM101 also experience reduction of the signs and symptoms of their disease. In addition to the improvement of the associated psoriatic arthritis, there is a reduction in the size and occurrence of psoriatic lesions and associated discomfort. As with treatment for RA, CM101 may be administered at various stages of the disease.

Another aspect of the present invention is a kit and a method of making a kit having a GBS toxin, preferably CM101, in a pharmaceutical composition along with instructions of how to administer the toxin for treatment of chronic inflammatory diseases.

5 The administration of CM101 to patients suffering from chronic inflammatory diseases has great utility, specifically in inhibiting the development of RA, reducing joint inflammation in RA patients, and reducing neovascularization in synovial tissues. Furthermore, the method of the present invention has great utility in inhibiting the development of psoriasis and psoriatic 10 arthritis, and particularly in reducing the likelihood of formation of abnormal vasculature which facilitates the inflammatory reactions causing the lesions. Other chronic inflammatory diseases that are characterized by angiogenesis may also be advantageously treated.

15 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 charts the wrist joint diameters of collagen arthritis-afflicted mice over time. The mice received 20 μ g/kg CM101, 60 μ g/kg CM101, or saline solution. CM101 treatment started on week 4 and continued through week 9. Measurements were taken prior to the start of the experiment (PRE) and at 2, 3, 20 4, 5, 7, 9 and 11 weeks.

Figure 2 charts the foot joint diameters of collagen arthritis-afflicted mice over time. The mice received 20 μ g/kg CM101, 60 μ g/kg CM101, or saline solution. CM101 treatment started on week 4 and continued through week 9. Measurements were taken prior to the start of the experiment (PRE) and at 2, 3, 25 4, 5, 7, 9, and 11 weeks.

Figure 3 charts the elbow joint diameters of collagen arthritis-afflicted mice over time. The mice received 20 μ g/kg CM101, 60 μ g/kg CM101, or saline solution. CM101 treatment started on week 4 and continued through week 9. Measurements were taken prior to the start of the experiment (PRE) and at 2, 3, 30 4, 5, 7, 9, and 11 weeks.

Figure 4 charts the knee joint diameters of collagen arthritis-afflicted mice over time. The mice received 20 μ g/kg CM101, 60 μ g/kg CM101, or saline

solution. CM101 treatment started on week 4 and continued through week 9. Measurements were taken prior to the start of the experiment (PRE) and at 2, 3, 4, 5, 7, 9, and 11 weeks.

5 Figure 5 depicts cross-sections of the knee joint of a normal mouse (A), a collagen arthritis-afflicted mouse (B), and a collagen arthritis-afflicted mouse treated with CM101 at 60 μ g/kg (C).

DETAILED DESCRIPTION OF THE INVENTION

CM101, a GBS toxin, is a polysaccharide molecule isolated from group B 10 β -hemolytic *Streptococcus* (GBS). Specifically, pathogenic group B β -hemolytic *streptococcus* produces a polysaccharide exotoxin. This exotoxin is the putative agent for a condition known as GBS pneumonia or "early-onset disease," which is characterized by sepsis, granulocytopenia, and respiratory distress, i.e. pulmonary hypertension and proteinaceous pulmonary edema (Hellerqvist, C.G. et al., *Studies* 15 *on group B β -hemolytic streptococcus I. Isolation and partial characterization of an extra-cellular toxin.*, *Pediatr. Res.*, 12:892-898 (1981)). It is believed that only newborn infants are susceptible to early onset disease because receptors for CM101 are present primarily on the lungs of newborns but that the receptors are lost approximately four to seven days after birth. CM101 is not known to cause 20 toxicity in older humans.

Isolated and purified CM101 has been shown to have toxic effects on sheep experimental models that mimic GBS infant pneumonia (Hellerqvist, C.G. et al., *Studies on group B β -hemolytic streptococcus I. Isolation and partial characterization of an extra-cellular toxin.*, *Pediatr. Res.*, 12:892-898 (1981)). In 25 the sheep model for neonatal early onset disease, GBS toxin causes pulmonary hypertension, increased pulmonary vascular permeability, granulocytopenia, and pulmonary sequestration of granulocytes.

CM101 has a molecular weight of approximately 300,000 Daltons and comprises N-acetyl-galactosamine, N-acetyl-glucosamine, glucose, galactose, and 30 mannose residues. Carboxylic acid residues are also believed to be an integral part of the molecule. Repeating active epitopes most likely play an important role in the pathophysiological response to CM101 by crosslinking receptors on target

endothelium (Hellerqvist, C.G. et al., *Early Results of a Phase I Trial of CM101 in Cancer Patients.*, Proceedings of the American Association of Cancer Research Annual Meeting, 36:224 (1995)).

A method of purification of a GBS toxin is provided in U.S. Patent No. 5,010,062. Preferably, however, the CM101 is purified according to the method taught in International Application No. PCT/US97/17535 incorporated herein by reference.

A source for GBS starting material for use in the method of the present invention may be obtained by culturing strains of Group B β -hemolytic 10 *Streptococcus* bacteria that have recently infected or are capable of infecting newborn infants. Isolates of such strains may be obtained from the blood or cerebral spinal fluid of infected infants.

GBS toxin as used herein is defined as any fraction or component isolated from natural or lysed GBS bacteria, or derived from media supernatants of lysed 15 and/or autoclaved GBS bacteria, and which has a biological activity as evidenced by induction of respiratory distress in the sheep assay (Hellerqvist, C.G. et al., *Studies on group B β -hemolytic streptococcus I. Isolation and partial characterization of an extra-cellular toxin.*, Pediatr. Res., 12:892-898 (1981)) or activation of complement and binding to neovasculature as demonstrated by a 20 peroxidase-antiperoxidase (PAP) assay of a tumor tissue specimen (Hellerqvist, C.G. et al., *Anti-tumor effects of GBS toxin: a polysaccharide exotoxin from group B β -hemolytic streptococcus*, J. Canc Res. Clin. Oncol., 120:63-70 (1993); and Hellerqvist, C.G. et al., *Early Results of a Phase I Trial of CM101 in Cancer Patients.*, Proceedings of the American Association of Cancer Research Annual Meeting, 36:224 (1995)). GBS toxin also means any synthetic polysaccharide with 25 the same structure or function as any GBS-derived molecule with the aforementioned activity.

Substantially pure GBS toxin means a preparation in which GBS toxin is greater than 40% pure (e.g., present in a concentration of at least about 40% by 30 weight), preferably at least approximately 60% pure, more preferably at least approximately 90% pure, and most preferably at least approximately 95% pure. The dosages described herein are for 95% pure GBS toxin. Dosages of lower

purity GBS toxin should be altered accordingly. The purity of GBS toxin is discussed in greater detail in PCT/US97/17535.

Rheumatoid arthritis or RA as used herein includes any disease that meets the diagnosis criteria set forth by the American Rheumatism Association for rheumatoid arthritis. These criteria are presented in Table 1 which is adapted from Rheumatology, Klippel and Dieppe, eds., Mosby, publ. (1994). RA also includes variants of RA such as juvenile RA, Still's disease, or Felty's syndrome.

TABLE 1

1987 Revised Diagnostic Criteria for the Classification of Rheumatoid Arthritis

1. Morning stiffness of at least one hour.*
2. Arthritis in at least 3 joint areas (right or left proximal interphalangeal, metacarpophalangeal, wrist, elbow, knee, ankle and metatarsophalangeal joints) with swelling or fluid.*
3. Arthritis of hand joints (at least one area swollen in a wrist, metatarsophalangeal or proximal interphalangeal joint).*
4. Symmetric joint swelling and involvement.*
5. Subcutaneous nodules.
6. Radiographic changes typical of rheumatoid arthritis.
7. Positive rheumatoid factor.

*Specified criteria that must be present for at least 6 weeks.

Treatment of RA as used herein includes the prevention, amelioration, decreased severity, inhibited progression, alleviation or elimination of RA or the symptoms thereof. People who may be treated include persons who have been diagnosed with early stage RA. The criteria for diagnosing RA are listed in Table 1. Persons genetically or environmentally predisposed to developing RA may also be treated, particularly if they have elevated RF levels. RF levels can be measured by agglutination tests such as the latex fixation test or the bentonite tube dilution tests. A mammal is in need of CM101 treatment if the mammal has RA or has a propensity to develop RA.

Reduction in the symptoms of RA may be measured by observing the degree of joint swelling or pain, or by radiographic, ultrasound or magnetic resonance

imaging of joint morphology. GBS toxin is particularly useful at reducing swelling. Also, heat is a symptom of RA, and the effectiveness of CM101 can therefore be measured by thermal photographs of joints.

Monitoring of CM101 can be achieved by measuring decreases in the level of

5 CD4+ cells. This can be achieved by flow cytometry. Monitoring for an increase in cytokine levels, such as tumor necrosis factor (TNF), IL-8, IL-6, IL-10, and macrophage inflammatory protein α (MIP α), is also possible. Furthermore, magnetic resonance imaging (MRI) is useful for visualizing vascularization and providing a relative measure of vessel density.

10 For the treatment of chronic inflammatory diseases, CM101 may be administered parenterally, topically, by internal injection of a bolus, by direct injection into affected joints, or by inhalation spray in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous,

15 intradermal, or intraperitoneal injections as well as intravenous, intra-arterial, intramuscular, intrasternal injection or infusion techniques. Parenteral administration is preferable and intravenous administration is most preferable. While a single intravenous administration may last up to 120 minutes, 5 to 60 minutes is the preferable duration range and 5 to 30 minutes is the most preferable

20 duration range.

For the treatment of chronic inflammatory diseases, CM101 is administered in doses of at least about 1 μ g/kg of the patient's body weight, preferably between about 1 and about 100 μ g/kg, more preferably between about 1 and about 50 μ g/kg, most preferably between about 1 and about 25 μ g/kg. It will be understood,

25 however, that the specific dose level for any particular patient will depend on a variety of factors including the age, body weight, general health, sex, diet, and severity of the inflammation or the disease of the patient undergoing therapy as well as the time of administration and route of administration of CM101.

CM101 may be administered daily, semi-weekly, weekly, semi-monthly or at

30 monthly intervals. Preferably, the interval will be in the range of one week to one month. Most preferably, the interval will be in the range of 7 days to 2 weeks. The severity of the patient's disease can be taken into account when determining

appropriate intervals for CM101 treatments. The appropriate interval can also be determined by assaying the levels of mature granulocytes in the patient's blood. The level of mature granulocytes is relevant to the timing of CM101 treatment because CM101 may cause granulocyte activation and subsequent depletion if 5 administered too frequently. Hence, future CM101 treatments may be more efficacious if the patient's supply of mature granulocytes has been replenished. One method for monitoring mature granulocyte levels is flow cytometry using the CD69 antigen to detect mature granulocytes.

CM101 treatments may continue over the course of several months, one year, 10 several years, or for the duration of the patient's lifetime. Alternatively, CM101 may be administered on a one-time only basis provided that symptoms of the disease do not reappear. Preferably, the patient will have at least about 5, 10 or 15 treatments.

The CM101-mediated reduction in joint swelling may be monitored by 15 external measurements of joint size, degree of tenderness upon palpation, degree of joint mobility, or radiological or other images of joint morphology. The CM101-mediated reduction of size, number, and degree of inflammation of psoriatic lesions will be evident upon visual observation.

CM101 should be administered in levels sufficient to reduce long-term pain in 20 the body of the patient. The skilled artisan will appreciate that increasing doses of CM101 should be administered until the patient experiences pain reduction and additional CM101 fails to effect greater pain amelioration. Intravenous administration could be set up such that the patient can control future dosages of CM101 according to the amount of pain they experience approximately 8 hours 25 after a CM101 treatment.

Another aspect of the present invention is an article of manufacture, such as a 30 kit, and a method for making the article of manufacture. The article includes a pharmaceutical composition comprising a GBS toxin, and particularly CM101, and a pharmaceutically acceptable carrier. The pharmaceutical composition may be placed in a suitable container, as is well known in the art. Also included are instructions for treatment of patients according to the methods of the present invention.

Without limitation to a particular theory, it is believed that GBS toxin, and especially CM101, operates as an anti-angiogenic agent which prevents the formation of new blood vessels. CM101 inhibits angiogenesis by binding dedifferentiated endothelial cells, the cells that are stimulated by hypoxic conditions to form new blood vessels. CM101 facilitates the binding and opsonization by C3 of endothelial cells, and these cells become the target of inflammatory cells, ultimately leading to the destruction of the endothelial cells.

Angiogenesis plays a key role in the pathogenesis of RA because synovial hypoxia induces the release of VEGF which causes the dedifferentiation of 10 endothelial cells and the formation of new blood vessels. Since the formation of these vessels is impeded by CM101 treatment, synovial tissue hyperplasia and lymphocyte infiltration are at least partially inhibited. As a result, the formation of new pannus is minimized, and existing pannus is reduced. These mechanisms are thought to underlie the CM101-mediated reduction in joint swelling, acute 15 inflammation, fibrin deposition, and pannus formation demonstrated herein.

Angiogenesis also plays a key role in the pathogenesis of psoriasis because it facilitates the infiltration of neutrophils and lymphocytes into the psoriatic lesion. Since the formation of new blood vessels is impeded by CM101 treatment, the formation, maintenance, and enlargement of psoriatic lesions are impaired.

RA and psoriasis are both diseases characterized by inflammation. Because inflammation is detrimental to persons suffering from RA or psoriasis, respectively, and there is evidence that CM101 works by stimulating inflammation, it might be expected that CM101 treatment would exacerbate these diseases.

Surprisingly, CM101 at least partially reduces the signs and symptoms of 25 inflammatory diseases such as RA and psoriasis.

It has been reported that AGM-1470 is an antiangiogenic compound which reduces joint swelling in rats with collagen arthritis (Peacock et al., *Angiogenesis inhibition suppresses collagen arthritis*, J. Exp. Med., 175:1135 (1992)). AGM-1470 is a synthetic analog of fumagillin, a naturally occurring fungal antibiotic 30 derived from *Aspergillus fumigatus fresenius* (Ingber et al., *Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth*, Nature, 348:555 (1990)). Since it is not a polysaccharide, AGM-1470 is structurally unrelated to

CM101. The mechanism of action of AGM-1470 also differs from CM101: AGM-1470's angiogenic activity is reported to not require induction of the host's immune system (Brem & Folkman, *Analysis of experimental antiangiogenic therapy*, J. Ped. Surg., 28:445 (1993)).

5 Another difference between AGM-1470 and CM101 is that AGM-1470 inhibits both physiological and pathological angiogenesis whereas CM101 only inhibits pathological angiogenesis. As their names suggest, pathological angiogenesis is associated with disease, and physiological angiogenesis occurs under normal, healthy circumstances. Wound healing, the female menstrual cycle, 10 and pregnancy are examples of physiological angiogenesis (Brem & Folkman, *Analysis of experimental antiangiogenic therapy*, J. Ped. Surg., 28:445 (1993)). Pathological angiogenesis occurs in diabetic retinopathy, hemangioma, cancer, psoriasis, RA, and osteoarthritis (Folkman et al., *Angiogenic factors*, Science, 235:442 (1987); Kimball et al., *Meeting report - angiogenesis in pannus formation*, Agents & Actions, 34:329 (1991)). Thus, in addition to its reported 15 role in inhibiting angiogenesis in pathological conditions such as tumors and RA, AGM-1470 inhibits wound healing (Brem et al., *Time dependent suppression of wound healing with the angiogenesis inhibitor, AGM-1470*, J. Cell Biol., 115: 403a (1991)) and female reproduction (D'Amato, Abstract from IBC Conference 20 on Angiogenesis), a clearly undesired effect. By comparison, CM101 does not inhibit placental or endometrial growth. CM101 not only fails to inhibit wound healing, but has actually been shown to facilitate it, as evidenced by a copending application filed concurrently herewith. Therefore, CM101 can be administered to 25 treat RA or psoriasis without causing the undesirable side effects of female infertility or compromised wound healing capacity that would result from AGM-1470 treatment.

The following examples are given for the purpose of illustrating the present invention and shall not be construed as being limitations on the scope or spirit of the instant invention.

EXAMPLES**Example 1: CM101 treatment reduces joint swelling.**

A mouse model for RA was utilized to assay the effects of CM101 on RA (Courtenay et al., *Immunisation against heterologous type II collagen induces arthritis in mice*, *Nature* 283: 666 (1980)). Male mice of the DBA/1 strain received intradermal injections of chicken Type II collagen at 4-6 sites on the back. The injected collagen was prepared as follows: 100 μ g collagen was dissolved in 100ml of 0.1M acetic acid and emulsified in an equal volume of Complete Freund's Adjuvant (0.5 mg/ml *M. butyricum*). Three weeks later, at week zero in the experiment, all animals were immunized by a single intraperitoneal injection of 100 μ g collagen. Two weeks after initial collagen injection, all animals tested positive for anti-chicken collagen antibodies. This was used as a diagnosis of incipient collagen arthritis.

The antibody-positive animals were divided into two experimental groups and one positive control group. From week 4 through week 9, all animals received intravenous 100 μ l injections three times per week. For the mice in the first experimental group (n=10), each injection contained 20 μ g/kg of CM101 dissolved in saline. For the second experimental group (n=10), 60 μ g/kg of saline-dissolved CM101 was injected each time. The positive control group (n=10), which previously received collagen injections and tested positive for anti-collagen antibodies, received physiological saline injections instead of CM101.

Joint inflammation was recorded by measurement with a special spring-loaded caliper (Starrett #1015 MA2). Measurements were made prior to the commencement of the experiment (PRE) and at weeks 2, 3, 4, 5, 7, 9, and 11. Two days after the final treatment on week 9, eighteen animals from the different groups were sacrificed and their front and hind limbs were formalin-fixed and sectioned for histological analysis. The remaining animals were not sacrificed until their joint measurements were taken in week 11.

Figures 1, 2, 3 & 4 show the diameter measurements of the wrist, foot, elbow and knee joints, respectively, of CM101-treated mice and control mice.

Prior to the initial collagen injection (PRE), all mice had small diameter joints. The joint measurements of CM101-treated and control mice continued to

be very similar in the weeks following the second round of collagen injections: joint diameters hovered around pre-treatment levels on weeks 2 and 3 and then increased tremendously between weeks 3 and 4. At week 4, the animals' joints were 35-70% larger than at the start of the experiment.

5 CM101 treatments began in week 4 and continued on a tri-weekly basis until week 9. During these weeks, the joint measurements of the animals which received CM101 were significantly smaller than the joint measurements of control mice, and the 60 μ g/kg dose of CM101 appeared more effective than 20 μ g/kg

CM101 in reducing joint size.

10 Even though they did not receive CM101 treatments after week 9, the CM101-treated animals exhibited additional reduction in joint size between weeks 9 and 11. By week 11, the joint measurements of mice treated with 20 μ g/kg CM101 or 60 μ g/kg CM101 were quite similar -- their joints were significantly smaller than the joints of control mice and had almost returned to their pre-
15 experimentation size.

Thus, CM101 diminishes pre-existing joint swelling. While the 60 μ g/kg dose reduces swelling more effectively than the 20 μ g/kg dose over short periods of time, the two dosages have similar long-term efficacy. CM101's therapeutic role in alleviating joint swelling is also supported by results of a similar experiment in
20 which collagen arthritis-afflicted mice were treated with 60 μ g/kg or 240 μ g/kg CM101 from weeks 2 through 9 (data not shown).

Example 2: CM101 reduces acute inflammation and pannus formation.

25 The protocol described above was followed except that the CM101 was administered at dosages of 0 μ g/kg, 60 μ g/kg and 240 μ g/kg in saline, and administration occurred three times a week from weeks 2 through 9. Histological sections were made 2 days after the final treatment at week 9.

As shown in Figure 5, CM101 diminishes the cellular manifestations of RA.

Under normal conditions (Fig. 5A), articular surfaces are curvilinear in shape
30 and lined by a thin synovial membrane. Just below the synovium lies a thick, even layer of hyaline cartilage (which is darkly stained in these preparations). Under the hyaline cartilage is the subchondral bone.

The joint of a mouse with collagen arthritis (Fig. 5B) exhibits flattening of the articular surface, active inflammation in the joint space, synovial hypertrophy and hyperplasia, pannus formation, and mild ankylosis. Destruction of the underlying hyaline cartilage and bone, which was caused by the pannus, is 5 evident.

Unlike its untreated counterpart, the joint of a CM101-treated mouse (Fig. 5C) lacks active inflammation and pannus formation. The hyaline cartilage layer is thick and even. The only morphological signs of arthritis are mild articular flattening, some loss of articular cartilage and subchondral bone, and fibrosis in 10 the area where pannus would otherwise have been.

Thus, CM101 treatment reduces periarticular inflammation, pannus formation, erosion of cartilage and bone, and ankylosis.

All publications and patent applications mentioned in this specification are 15 herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto 20 without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. A method for treating a patient with a chronic inflammatory disease, which method comprises:

5 administering a group B β -hemolytic *Streptococcus* (GBS) toxin to the patient in a quantity sufficient to reduce the likelihood of formation of new blood vessels at a site of disease.

2. The method of claim 1 wherein the chronic inflammatory disease is angiogenesis dependent.

10

3. The method of claim 1 wherein the chronic inflammatory disease is selected from the group consisting of rheumatoid arthritis and psoriasis.

4. The method of claim 1 wherein the GBS toxin is CM101.

15

5. The method of claim 4 wherein the CM101 is substantially pure.

6. The method of claim 5 wherein the CM101 has a purity of at least approximately 90%.

20

7. The method of claim 1 wherein the GBS toxin is administered parenterally.

8. The method of claim 7 wherein the GBS toxin is administered intravenously.

25

9. The method of claim 1 wherein the patient is at least 4 days old.

10. The method of claim 9 wherein the patient is at least 7 days old.

30

11. The method of claim 1 wherein the treatment is maintained by repeatedly administering the GBS toxin to the patient at an interval in the range of one week to one month.

12. The method of claim 11 wherein the interval is in the range of 7 days to 2 weeks.
13. The method of claim 1 wherein the GBS toxin is administered at a level of 1 5 μ g/kg to 100 μ g/kg weight.
14. The method of claim 13 wherein the GBS toxin is administered at a level of 1 μ g/kg to 25 μ g/kg body weight.
- 10 15. The method of claim 1 wherein the GBS toxin is administered in a quantity sufficient to reduce pain in the body of the patient approximately 8 hours after the administration of the GBS toxin.
- 15 16. The method of claim 1 wherein the GBS toxin is administered in a quantity sufficient to reduce swelling in the joints of the body.
17. The method of claim 1 wherein the GBS toxin is administered in a quantity sufficient to inhibit angiogenesis in synovial tissues of the patient.
- 20 18. The method of claim 3 wherein the disease is psoriasis and the GBS toxin is administered in a quantity sufficient to diminish psoriatic lesions.
19. A method for treating a chronic inflammatory disease that is angiogenesis dependent, which method comprises:
25 administering a compound which reduces the likelihood of formation of new blood vessels at a site of disease, but which does not inhibit wound healing.
20. The method of claim 19 wherein the compound is a group B β -hemolytic *Streptococcus* (GBS) toxin.
- 30 21. The method of claim 20 wherein the GBS toxin is CM101.

22. The method of claim 21 wherein the CM101 is substantially pure.

23. The method of claim 22 wherein the CM101 has a purity of at least approximately 90%.

5

24. A method for treating rheumatoid arthritis in the body of a patient, which method comprises:

administering a group B β -hemolytic *Streptococcus* (GBS) toxin to the patient in a quantity sufficient to reduce signs or symptoms of rheumatoid arthritis.

10

25. The method of claim 24 wherein the GBS toxin is CM101.

26. The method of claim 25 wherein the CM101 has a purity of at least approximately 90%.

15

27. A method for treating psoriasis in the body of a patient, which method comprises:

administering a group B β -hemolytic *Streptococcus* (GBS) toxin to the patient in a quantity sufficient to reduce signs or symptoms of psoriasis.

20

28. The method of claim 27 wherein the GBS toxin is CM101.

29. The method of claim 28 wherein the CM101 has a purity of at least approximately 90%.

25

30. An article of manufacture comprising:

(a) a pharmaceutical composition having

(i) a group B β -hemolytic *Streptococcus* (GBS) toxin, and

(ii) a pharmaceutically acceptable carrier, and

30

(b) instructions for administering the pharmaceutical composition to a patient for treatment of a chronic inflammatory disease.

31. The article of claim 30 wherein the GBS toxin is CM101.
32. The article of claim 31 wherein the CM101 has a purity of at least approximately 90%.
- 5 33. The article of claim 30 wherein the instructions describe administration of the pharmaceutical composition in a quantity sufficient to reduce the likelihood of formation of new blood vessels at a site of disease.
- 10 34. The article of claim 30 wherein the instructions describe administration of the pharmaceutical composition to treat rheumatoid arthritis.
35. The article of claim 30 wherein the instructions describe administration of the pharmaceutical composition to treat psoriasis.
- 15 36. A method of making an article of manufacture, which method comprises:
combining
 - (a) a container including a pharmaceutical composition comprising
 - (i) a group B β -hemolytic *Streptococcus* (GBS) toxin, and
 - (ii) a pharmaceutically acceptable carrier, and
 - (b) labelling instructions for treating a patient having a chronic inflammatory disease by administering the pharmaceutical composition to the patient.
37. The article of claim 36 wherein the GBS toxin is CM101.
- 25 38. The method of claim 37 wherein the CM101 has a purity of at least approximately 90%.
39. The method of claim 36 wherein the instructions describe administration of the pharmaceutical composition in a quantity sufficient to reduce the likelihood of formation of new blood vessels at a site of disease.

40. The method of claim 36 wherein the instructions describe administration of the pharmaceutical composition to treat rheumatoid arthritis.

41. The method of claim 36 wherein the instructions describe administration of 5 the pharmaceutical composition to treat psoriasis.

1/7




FIG. 1

2/7




FIG. 2

3/7




FIG. 3

4/7




FIG. 4

5/7



FIG 5A

6/7



FIG 5B

7/7



FIG 5C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/01852

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K35/74 A61K31/715

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 91 04048 A (VANDERBILT UNIVERSITY) 4 April 1991 see page 3, line 25 - line 31; claims & US 5 010 062 A cited in the application --- J. FOLKMAN ET AL.: "ANGIOGENIC FACTORS" SCIENCE, vol. 235, 23 January 1987, LANCASTER, PA US, pages 442-447, XP002065073 cited in the application see page 446, right-hand column, line 21 - line 33 --- -/-	1-41
Y		1-3, 7-20, 24, 27, 30, 33-36, 39-41

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

15 May 1998

Date of mailing of the international search report

08.07.1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ryckebosch, A

1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/01852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>C.G. HELLERQVIST ET AL.: "PRELIMINARY RESULTS OF A PHASE I TRIAL OF CM101 IN CANCER PATIENTS." JOURNAL OF CELLULAR BIOCHEMISTRY, no. SUPPL. 19B, 1995, NEW YORK, N.Y., US, page 26 XP002054992 see the whole document</p> <p>---</p>	4-6, 21-23, 25,26, 28,29, 31,32, 37,38
P,X	<p>WO 97 41844 A (ALCON LABORATORIES, INC.) 13 November 1997 see page 1, line 1 - line 26; claims 1,2,15,16 see page 6, line 10 see page 20, line 2 - line 9</p> <p>-----</p>	1-41

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US 98/01852**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No.
PCT/US 98/01852

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9104048	A 04-04-1991	US 5010062	A	23-04-1991
		AT 136222	T	15-04-1996
		AU 626733	B	06-08-1992
		AU 6513590	A	18-04-1991
		CA 2042032	A	26-03-1991
		CA 2042032	C	10-10-1995
		DE 69026371	D	09-05-1996
		DE 69026371	T	01-08-1996
		EP 0445280	A	11-09-1991
		ES 2087915	T	01-08-1996
		JP 6062426	B	17-08-1994
		JP 4501870	T	02-04-1992
WO 9741844	A 13-11-1997	AU 2438297	A	26-11-1997